X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Cabazitaxel Intravenous Powder (generic for Jevtana Kit®), is a Microtubule inhibitor, available in the 60mg/1.5mL (40mg/mL) strength used fo the treatment of Prostate cancer.
Lead Product(s): Cabazitaxel
Therapeutic Area: Oncology Product Name: Cabazitaxel-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Natco Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
Cabazitaxel intravenous powder of strength 60mg/1.5ml (40mg/ml), is an antineoplastic agent and a microtubule inhibitor used in the treatment of prostate cancer.
Lead Product(s): Cabazitaxel
Therapeutic Area: Oncology Product Name: Cabazitaxel-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Natco Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2022
Details:
Dabigatran Etexilate Capsules (generic for Pradaxa®), is good at preventing blood clots that can cause a stroke or heart attack, but it can be very expensive and must be used carefully in patients with kidney problems.
Lead Product(s): Dabigatran Etexilate Mesylate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Dabigatran Etexilate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2022
Details:
Miglustat Capsules (generic for Zavesca), 100mg strength, is an inhibitor of the enzyme glucosylceramide synthase, which is a glucosyl transferase enzyme responsible for first step in synthesis of most glycosphingolipids.
Lead Product(s): Miglustat
Therapeutic Area: Genetic Disease Product Name: Miglustat-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2022
Details:
Penicillamine Capsules, USP (generic for Cuprimine®), a chelating agent recommended for the removal of excess copper in patients with Wilson's disease also in cystinuria, and in patients with severe, active rheumatoid arthritis.
Lead Product(s): Penicillamine
Therapeutic Area: Genetic Disease Product Name: Pencillamine-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Aggrega Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Details:
Lacosamide Tablets, USP (generic version of Vimpat), indicated for the prevention and control of seizures, enhances the slow inactivation of voltage-gated sodium channels without affecting the fast inactivation of voltage-gated sodium channels.
Lead Product(s): Lacosamide
Therapeutic Area: Neurology Product Name: Lacosamide-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: MSN Laboratories
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
The received FDA approval will allow Breckenridge, to launch generic Teriflunomide in the US market from the beginning of 2023 onwards. Teriflunomide, a small molecule is a generic of Aubagio® available in 7mg & 14mg Tablets.
Lead Product(s): Teriflunomide
Therapeutic Area: Immunology Product Name: Teriflunomide-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Axplora
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2021
Details:
Everolimus is the generic name for the trade name drug Afinitor. Breckenridge has launched 10mg strength of Everolimus Tablets used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours.
Lead Product(s): Everolimus
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Natco Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 01, 2021
Details:
Breckenridge previously launched Succinylcholine Chloride Injection, USP, 20mg/mL under this agreement, which is now available from Breckenridge as a carton of 25 vials.
Lead Product(s): Succinylcholine Chloride
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Aggrega Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 22, 2021
Details:
Breckenridge plans to launch Everolimus Tablets in 2.5mg, 5mg and 7.5mg strengths during the second quarter of 2021 in a blister card packaging configuration.
Lead Product(s): Everolimus
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Natco Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
